Nordic Issuing

Ongoing case

Prostatype Genomics AB

Back to all cases

Prostatype Genomics AB

27 Jan - 17 Feb 2022Warrant exercise

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By giving a comprehensive assessment of the aggressiveness of the prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Their vision is that doctors and patients, confronted with diagnosed prostate cancer, have full confidence in their treatment decisions.

Prostatype Genomics’ mission is to make a difference in prostate cancer patients’ lives through the discovery and commercialization of transformative tests to guide treatment decisions. They can thereby increase quality of life and peace-of-mind for patients and simultaneously reduce health care costs. Prostatype Genomics will achieve this by making Prostatype the global test system of choice for newly diagnosed prostate cancer patients.

Read more on the company's website

The offer in summary

Subscription period: 27 January- 17 February 2022

Price per share: SEK 10.90

Trading with warrant: Until 15 February 2022

Payment day: 17 February 2022

Marketplace: First North Stockholm

Financial advisor: Sedermera Corporate Finance


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.